Form 4 for VNRX VOLITIONRX LTD
Accepted 2025-08-06 00:00:00 ET · period of report 2025-08-05 · accession 0001477932-25-005494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-06 | 2025-08-05 | VNRX | Reynolds Cameron John | Pres, CEO, Dir | P - Purchase | $0.64 | +78.1K | 2.61M | +3% | +$50.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-05 | P | A | 78,125 | $0.64 | 2,609,847 | D | — | — | (F1) Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. |